These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [The effects of betahistine on the function of equilibrium system]. Kubiczkowa J Otolaryngol Pol; 1997; 51 Suppl 25():230-9. PubMed ID: 9757700 [TBL] [Abstract][Full Text] [Related]
23. Betahistine treatment in managing vertigo and improving vestibular compensation: clarification. Lacour M J Vestib Res; 2013; 23(3):139-51. PubMed ID: 24177346 [TBL] [Abstract][Full Text] [Related]
24. Flunarizine and betahistine. Two different therapeutic approaches in vertigo compared in a double-blind study. Elbaz P Acta Otolaryngol Suppl; 1988; 460():143-8. PubMed ID: 3074614 [TBL] [Abstract][Full Text] [Related]
25. [Epidemiology, clinical features and betaserc therapy of vertigo in initial and reversible cerebrovascular pathology]. Gornostaeva GV; Varakin IuIa; Prokopovich ME; Alekseeva NS; Fedin PA; Chechetkin AO Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(9):14-7. PubMed ID: 16250576 [TBL] [Abstract][Full Text] [Related]
32. [Current methods for diagnosis and treatment of iatrogenic ototoxicity]. Pavlyushina EM; Morozova SV Vestn Otorinolaringol; 2007; (5):38-43. PubMed ID: 18175413 [No Abstract] [Full Text] [Related]
33. [Betaserc in symptomatic therapy of multiple sclerosis]. Boĭko AN; Derevianko SN; Luchikhin LA; Slanova AV; Gusev EI Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(1):42-5. PubMed ID: 11842621 [No Abstract] [Full Text] [Related]
34. [Seven principles in the treatment of vestibular vertigo and results of the study of VIRTUOSO]. Zamergrad MV; Parfenov VA; Matsnev EI; Morozova SV; Melnikov OA; Sigaleva EE; Antonenko LM Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(12):106-110. PubMed ID: 29376992 [TBL] [Abstract][Full Text] [Related]
35. [The use of betaserk in patients with cochlear-vestibular disorders]. Kadymov MI; Poliakova TS; Vladimirova TN Vestn Otorinolaringol; 1998; (5):49-50. PubMed ID: 9793432 [TBL] [Abstract][Full Text] [Related]
36. Improving the quality of life in patients with vestibular disorders: the role of medical treatments and physical rehabilitation. Mira E Int J Clin Pract; 2008 Jan; 62(1):109-14. PubMed ID: 17537195 [TBL] [Abstract][Full Text] [Related]
37. [Betaserk efficiency in cochlear and vestibular disorders in the regional surdocenter]. Pekaskiĭ SI Vestn Otorinolaringol; 2001; (3):61. PubMed ID: 11510053 [TBL] [Abstract][Full Text] [Related]
38. [Clinical use of Bethahistine mesylate]. Satake K; Ogino H; Yamaguchi H Jibiinkoka; 1969 Dec; 41(12):989-92. PubMed ID: 4984188 [No Abstract] [Full Text] [Related]
39. [Betaserc treatment of acute disorders of cerebral circulation with vestibulo-ataxic and cochleo-vestibular syndromes]. Berdichevskiĭ MIa; Karmirian SA; Geĭko II; Miroshnichenko VE; Parkhaeva TN; Popova VG; Timchenko LV; Filina TV; Aristova LA Vestn Otorinolaringol; 2002; (4):32-3. PubMed ID: 12400131 [No Abstract] [Full Text] [Related]
40. [Assessment of betahistine dihydrochloride effectiveness in the treatment of vertigo of a different aetiology based on videonystagmography test results]. Kantor I; Jurkiewicz D Pol Merkur Lekarski; 2006 Mar; 20(117):318-21. PubMed ID: 16780265 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]